
    
      This post-market study is a single-arm, prospective, multi-center Registry. It is designed to
      assess 36-month safety and effectiveness of this FDA approved product in a post-approval
      setting, and to support the continued assessment of Spiration Valve System therapy for the
      treatment of severe emphysema in the United States.

      Subjects who are eligible and consent to be in this study, will be monitored for outcome data
      from baseline through 3 years post-first implant.
    
  